

Adam D Devore

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4635712/publications.pdf>

Version: 2024-02-01

253
papers

10,330
citations

61857

43
h-index

43802

91
g-index

268
all docs

268
docs citations

268
times ranked

10309
citing authors

#	ARTICLE	IF	CITATIONS
1	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. <i>Lancet</i> , The, 2018, 392, 1519-1529.	6.3	1,179
2	Angiotensinâ€Nepirilysin Inhibition in Acute Decompensated Heart Failure. <i>New England Journal of Medicine</i> , 2019, 380, 539-548.	13.9	848
3	Medical Therapy for Heart Failure WithâRreduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2018, 72, 351-366.	1.2	775
4	Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2476-2486.	1.2	671
5	Association of the Hospital Readmissions Reduction Program Implementation With Readmission and Mortality Outcomes in Heart Failure. <i>JAMA Cardiology</i> , 2018, 3, 44.	3.0	346
6	Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2365-2383.	1.2	327
7	Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 741-748.	1.6	235
8	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , the, 2019, 7, 618-628.	5.5	207
9	Heart Failure With Preserved EjectionâRfraction and Diabetes. <i>Journal of the American College of Cardiology</i> , 2019, 73, 602-611.	1.2	182
10	HeartâRfailure and Atrial Fibrillation, LikeâRfireâRandâRFury. <i>JACC: Heart Failure</i> , 2019, 7, 447-456.	1.9	178
11	Trends in Noncardiovascular Comorbidities Among Patients Hospitalized for Heart Failure. <i>Circulation: Heart Failure</i> , 2018, 11, e004646.	1.6	134
12	Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial. <i>Circulation</i> , 2019, 139, 2285-2288.	1.6	129
13	Trends in 30-Day Readmission Rates for Patients Hospitalized With Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	127
14	Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the <scp>RELAX</scp> trial. <i>European Journal of Heart Failure</i> , 2017, 19, 893-900.	2.9	123
15	Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: Findings from Get With The Guidelinesâ€Heart Failure registry. <i>American Heart Journal</i> , 2016, 182, 9-20.	1.2	115
16	Initiation, Continuation, or Withdrawal of Angiotensinâ€Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	104
17	The Future of Wearables in HeartâRfailure Patients. <i>JACC: Heart Failure</i> , 2019, 7, 922-932.	1.9	101
18	Decongestion Strategies and Renin-Angiotensin-Aldosterone System Activation in Acute HeartâRfailure. <i>JACC: Heart Failure</i> , 2015, 3, 97-107.	1.9	95

#	ARTICLE	IF	CITATIONS
19	Kidney Function and Outcomes in Patients Hospitalized With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 78, 330-343.	1.2	90
20	Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes. <i>JACC: Heart Failure</i> , 2017, 5, 1-13.	1.9	84
21	Reassessing Recipient Mortality Under the New Heart Allocation System. <i>JACC: Heart Failure</i> , 2020, 8, 548-556.	1.9	83
22	Timing and Causes of Readmission After Acute Heart Failure Hospitalization—Insights From the Heart Failure Network Trials. <i>Journal of Cardiac Failure</i> , 2016, 22, 875-883.	0.7	78
23	Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2022, 7, 17.	3.0	77
24	Association of 30-Day Readmission Metric for Heart Failure Under the Hospital Readmissions Reduction Program With Quality of Care and Outcomes. <i>JACC: Heart Failure</i> , 2016, 4, 935-946.	1.9	68
25	Rhythm Control Versus Rate Control in Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction: Insights From Get With The Guidelines—Heart Failure. <i>Journal of the American Heart Association</i> , 2019, 8, e011560.	1.6	68
26	Effect of a Hospital and Postdischarge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 314.	3.8	68
27	Target Doses of Heart Failure Medical Therapy and Blood Pressure. <i>JACC: Heart Failure</i> , 2019, 7, 350-358.	1.9	67
28	Health Status Disparities by Sex, Race/Ethnicity, and Socioeconomic Status in Outpatients With Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 465-473.	1.9	65
29	Comparison of New York Heart Association Class and Patient-Reported Outcomes for Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 522.	3.0	62
30	Rationale and design of the comparison of sacubitril/valsartan versus Enalapril on Effect on natriuretic peptide in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial. <i>American Heart Journal</i> , 2018, 198, 145-151.	1.2	60
31	Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial. <i>European Heart Journal</i> , 2019, 40, 3345-3352.	1.0	59
32	Sex and Race/Ethnicity-Related Disparities in Care and Outcomes After Hospitalization for Coronary Artery Disease Among Older Adults. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, S36-44.	0.9	57
33	Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure. <i>JAMA Cardiology</i> , 2020, 5, 202.	3.0	57
34	Left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: outcomes following an acute heart failure hospitalization. <i>ESC Heart Failure</i> , 2017, 4, 432-439.	1.4	56
35	Splanchnic nerve block for decompensated chronic heart failure: splanchnic-HF. <i>European Heart Journal</i> , 2018, 39, 4255-4256.	1.0	54
36	Increasing the United States heart transplant donor pool with donation after circulatory death. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 159, e307-e309.	0.4	53

#	ARTICLE	IF	CITATIONS
37	Factors Associated With and Prognostic Implications of Cardiac Troponin Elevation in Decompensated Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2017, 2, 136.	3.0	50
38	Trends in Hospice Discharge and Relative Outcomes Among Medicare Patients in the Get With The Guidelinesâ€“Heart Failure Registry. <i>JAMA Cardiology</i> , 2018, 3, 917.	3.0	50
39	Inâ€“Hospital Worsening Heart Failure and Associations With Mortality, Readmission, and Healthcare Utilization. <i>Journal of the American Heart Association</i> , 2014, 3, .	1.6	48
40	Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). <i>American Journal of Cardiology</i> , 2016, 117, 404-411.	0.7	47
41	Can Vaccinations Improve Heartâ€“Failureâ€“Outcomes?. <i>JACC: Heart Failure</i> , 2017, 5, 194-203.	1.9	47
42	Outcomes with ambulatory advanced heart failure from the Medical Arm of Mechanically Assisted Circulatory Support (MedaMACS) Registry. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 408-417.	0.3	47
43	Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetesâ€“Mellitus and HFrEF. <i>JACC: Heart Failure</i> , 2020, 8, 469-480.	1.9	47
44	Has Public Reporting of Hospital Readmission Rates Affectedâ€“Patient Outcomes?. <i>Journal of the American College of Cardiology</i> , 2016, 67, 963-972.	1.2	46
45	Liver function tests in patients with acute heart failure and associated outcomes: insights from <scp>ASCENDâ€“HF</scp>. <i>European Journal of Heart Failure</i> , 2016, 18, 424-432.	2.9	45
46	Splanchnic Nerve Block for Chronicâ€“Heartâ€“Failure. <i>JACC: Heart Failure</i> , 2020, 8, 742-752.	1.9	44
47	Change the management of patients with heart failure: Rationale and design of the CHAMP-HF registry. <i>American Heart Journal</i> , 2017, 189, 177-183.	1.2	43
48	Heartâ€“Failure Hospitalization and Guideline-Directed Prescribing Patterns Among Heartâ€“Failure With Reduced Ejection Fraction Patients. <i>JACC: Heart Failure</i> , 2021, 9, 28-38.	1.9	43
49	Clinical profiles in acute heart failure: an urgent need for a new approach. <i>ESC Heart Failure</i> , 2019, 6, 464-474.	1.4	42
50	Achieving a Maximally Tolerated Î²-Blocker Dose in Heart Failure Patients. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2542-2550.	1.2	41
51	Race/Ethnic Differences in Outcomes Among Hospitalized Medicare Patients With Heart Failure and Preserved Ejectionâ€“Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 483-493.	1.9	41
52	Sacubitril/Valsartan in Advanced Heartâ€“Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 789-799.	1.9	39
53	Temporal Trends and Factors Associated With Cardiac Rehabilitation Participation Among Medicare Beneficiaries With Heartâ€“Failure. <i>JACC: Heart Failure</i> , 2021, 9, 471-481.	1.9	38
54	Association of Hospital Performance Based on 30-Day Risk-Standardized Mortality Rate With Long-term Survival After Heart Failure Hospitalization. <i>JAMA Cardiology</i> , 2018, 3, 489.	3.0	37

#	ARTICLE	IF	CITATIONS
55	Transient and persistent worsening renal function during hospitalization for acute heart failure. <i>American Heart Journal</i> , 2014, 168, 891-900.	1.2	36
56	Medical Management of Patients With a Left Ventricular Assist Device for the Non-Left Ventricular Assist Device Specialist. <i>JACC: Heart Failure</i> , 2017, 5, 621-631.	1.9	36
57	Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States. <i>Circulation: Heart Failure</i> , 2018, 11, e005400.	1.6	36
58	Medical Management of Heart Failure With Reduced Ejection Fraction in Patients With Advanced Renal Disease. <i>JACC: Heart Failure</i> , 2019, 7, 371-382.	1.9	36
59	Relation of Dyspnea Severity on Admission for Acute Heart Failure With Outcomes and Costs. <i>American Journal of Cardiology</i> , 2015, 115, 75-81.	0.7	35
60	Clinical Implications of Serum Albumin Levels in Acute Heart Failure: Insights From DOSE-AHF and ROSE-AHF. <i>Journal of Cardiac Failure</i> , 2016, 22, 884-890.	0.7	35
61	Discordant Perceptions of Prognosis and Treatment Options Between Physicians and Patients With Advanced Heart Failure. <i>JACC: Heart Failure</i> , 2017, 5, 663-671.	1.9	33
62	Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 1390-1398.	2.9	33
63	Angiotensin Receptor-Nephrilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1034-1048.	1.2	32
64	Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AF. <i>Europace</i> , 2016, 18, 1135-1142.	0.7	31
65	Association of the Affordable Care Act's Medicaid Expansion With Care Quality and Outcomes for Low-Income Patients Hospitalized With Heart Failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004729.	0.9	31
66	Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 933-941.	1.9	31
67	The Impact of Worsening Heart Failure in the United States. <i>Heart Failure Clinics</i> , 2015, 11, 603-614.	1.0	30
68	Vaccination Trends in Patients With Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 844-855.	1.9	30
69	Representativeness of a Heart Failure Trial by Race and Sex. <i>JACC: Heart Failure</i> , 2019, 7, 980-992.	1.9	30
70	Acute Heart Failure. <i>JACC: Heart Failure</i> , 2017, 5, 329-336.	1.9	29
71	First-in-human experience with Aortix intraaortic pump. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 428-433.	0.7	29
72	Torsemide Versus Furosemide in Heart Failure Patients. <i>Journal of Cardiovascular Pharmacology</i> , 2015, 65, 438-443.	0.8	28

#	ARTICLE	IF	CITATIONS
73	Angiotensin Receptor Neprilysin Inhibition in Heart Failure: Mechanistic Action and Clinical Impact. <i>Journal of Cardiac Failure</i> , 2015, 21, 741-750.	0.7	28
74	High early event rates in patients with questionable eligibility for advanced heart failure therapies: Results from the Medical Arm of Mechanically Assisted Circulatory Support (Medamacs) Registry. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 722-730.	0.3	28
75	Discharge heart rate and β -blocker dose in patients hospitalized with heart failure: Findings from the OPTIMIZE-HF registry. <i>American Heart Journal</i> , 2016, 173, 172-178.	1.2	28
76	Splanchnic Nerve Block Mediated Changes in Stressed Blood Volume in Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 293-300.	1.9	28
77	Medical Management of Patients With Continuous-Flow Left Ventricular Assist Devices. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2014, 16, 283.	0.4	27
78	Aerobic exercise training and general health status in ambulatory heart failure patients with a reduced ejection fraction—Findings from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) trial. <i>American Heart Journal</i> , 2017, 186, 130-138.	1.2	27
79	Leveraging Behavioral Economics to Improve Heart Failure Care and Outcomes. <i>Circulation</i> , 2017, 136, 765-772.	1.6	27
80	The burden of noncardiac comorbidities and association with clinical outcomes in an acute heart failure trial—Insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2020, 22, 1022-1031.	2.9	27
81	Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial. <i>Circulation: Heart Failure</i> , 2021, 14, e007034.	1.6	27
82	Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	26
83	Provider Perspectives on the Feasibility and Utility of Routine Patient-Reported Outcomes Assessment in Heart Failure: A Qualitative Analysis. <i>Journal of the American Heart Association</i> , 2020, 9, e013047.	1.6	26
84	Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the <sc>FIGHT</sc> trial. <i>ESC Heart Failure</i> , 2018, 5, 1035-1043.	1.4	25
85	Improvement in Left Ventricular Ejection Fraction in Outpatients With Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2020, 13, e006833.	1.6	25
86	Sex Differences in the Management and Outcomes of Heart Failure With Preserved Ejection Fraction in Patients Presenting to the Emergency Department With Acute Heart Failure. <i>Journal of Cardiac Failure</i> , 2016, 22, 781-788.	0.7	24
87	Temporal Trends and Variation in Early Scheduled Follow-Up After a Hospitalization for Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	24
88	Characteristics and Outcomes of COVID-19 in Patients on Left Ventricular Assist Device Support. <i>Circulation: Heart Failure</i> , 2021, 14, e007957.	1.6	24
89	Relation of Elevated Heart Rate in Patients With Heart Failure With Reduced Ejection Fraction to One-Year Outcomes and Costs. <i>American Journal of Cardiology</i> , 2016, 117, 946-951.	0.7	23
90	Serum Bicarbonate in Acute Heart Failure: Relationship to Treatment Strategies and Clinical Outcomes. <i>Journal of Cardiac Failure</i> , 2016, 22, 738-742.	0.7	23

#	ARTICLE	IF	CITATIONS
91	Resting Heart Rate and Long-term Outcomes Among the African American Population. <i>JAMA Cardiology</i> , 2017, 2, 172.	3.0	23
92	Regional Variations in Heart Failure Quality and Outcomes: Get With The Guidelinesâ€“Heart Failure Registry. <i>Journal of the American Heart Association</i> , 2021, 10, e018696.	1.6	23
93	Loop diuretic dose adjustments after a hospitalization for heart failure: insights from <scp>ASCENDâ€“HF</scp>. <i>European Journal of Heart Failure</i> , 2015, 17, 340-346.	2.9	22
94	Cluster-Randomized Trial of Personalized Site Performance Feedback in Get With The Guidelines-Heart Failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 421-427.	0.9	22
95	Guideline-Appropriate Care and In-Hospital Outcomes in Patients With Heart Failure in Teaching and Nonteaching Hospitals. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 757-766.	0.9	22
96	The impact of a failing right heart in patients supported by intra-aortic balloon counterpulsation. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 709-718.	0.4	22
97	Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure: Rationale and design of CONNECT-HF. <i>American Heart Journal</i> , 2020, 220, 41-50.	1.2	22
98	Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice. <i>JAMA Cardiology</i> , 2021, 6, 267.	3.0	22
99	Transplanting thoracic COVID-19 positive donors: An institutional protocol and report of the first 14 cases. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 1376-1381.	0.3	22
100	Medicare Expenditures by Race/Ethnicity After Hospitalization for Heart Failure Withâ€“Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2018, 6, 388-397.	1.9	21
101	Ventricular Conduction and Long-Term Heart Failure Outcomes and Mortality in African Americans. <i>Circulation: Heart Failure</i> , 2015, 8, 243-251.	1.6	20
102	Thinking Outside the Box: Treating Acute Heart Failure Outside the Hospital to Improve Care and Reduce Admissions. <i>Journal of Cardiac Failure</i> , 2015, 21, 667-673.	0.7	20
103	Early Ambulation Among Hospitalized Heart Failure Patients Is Associated With Reduced Length of Stay and 30-Day Readmissions. <i>Circulation: Heart Failure</i> , 2018, 11, e004634.	1.6	20
104	Association of Changes in Heartâ€“Failure Treatment With Patientsâ€™ Health Status. <i>JACC: Heart Failure</i> , 2019, 7, 615-625.	1.9	20
105	Home Health Care Use and Post-Discharge Outcomes After Heartâ€“Failure Hospitalizations. <i>JACC: Heart Failure</i> , 2020, 8, 1038-1049.	1.9	20
106	Assessing Consequences of Intraaortic Balloon Counterpulsation Versus Left Ventricular Assist Devices at the Time of Heart Transplantation. <i>ASAIO Journal</i> , 2016, 62, 232-239.	0.9	19
107	Comparison of Hydralazine/Nitrate and Angiotensin Receptor Nephilysin Inhibitor Use Among Black Versus Nonblack Americans With Heart Failure and Reduced Ejection Fraction (from CHAMP-HF). <i>American Journal of Cardiology</i> , 2019, 124, 1900-1906.	0.7	19
108	Spironolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1097-1105.	0.8	19

#	ARTICLE	IF	CITATIONS
109	Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial. <i>JACC: Heart Failure</i> , 2020, 8, 834-843.	1.9	19
110	Changes in Care Delivery for Patients With Heart Failure During the COVID-19 Pandemic: Results of a Multicenter Survey. <i>Journal of Cardiac Failure</i> , 2020, 26, 635-636.	0.7	19
111	Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. <i>Diabetes Care</i> , 2021, 44, 1219-1227.	4.3	19
112	Predictors of Hypertension Control in a Diverse General Cardiology Practice. <i>Journal of Clinical Hypertension</i> , 2010, 12, 570-577.	1.0	18
113	Selecting a Noninvasive Imaging Study After an Inconclusive Exercise Test. <i>Circulation</i> , 2010, 122, 1514-1518.	1.6	18
114	Techniques and applications of perioperative therapeutic plasma exchange. <i>Current Opinion in Anaesthesiology</i> , 2014, 27, 57-64.	0.9	18
115	Association of post-discharge specialty outpatient visits with readmissions and mortality in high-risk heart failure patients. <i>American Heart Journal</i> , 2019, 212, 101-112.	1.2	18
116	Influence of donor brain death duration on outcomes following heart transplantation: A United Network for Organ Sharing Registry analysis. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 159, 1345-1353.e2.	0.4	18
117	Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2020, 13, e006645.	1.6	18
118	Donation After Circulatory Death in Heart Transplantation: History, Outcomes, Clinical Challenges, and Opportunities to Expand the Donor Pool. <i>Journal of Cardiac Failure</i> , 2022, 28, 1456-1463.	0.7	18
119	Patient Selection for Advanced Heart Failure Therapy Referral. <i>Critical Pathways in Cardiology</i> , 2014, 13, 1-5.	0.2	17
120	Characteristics and Outcomes of Patients With Heart Failure and Discordant Findings by Right-Sided Heart Catheterization and Cardiopulmonary Exercise Testing. <i>American Journal of Cardiology</i> , 2014, 114, 1059-1064.	0.7	17
121	Long-term outcomes for heart failure patients with and without diabetes: From the Get With The Guidelines® Heart Failure Registry. <i>American Heart Journal</i> , 2019, 211, 1-10.	1.2	17
122	Trends in the Use of Guideline-Directed Therapies Among Dialysis Patients Hospitalized With Systolic Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 649-661.	1.9	16
123	Association of Electronic Health Record Use With Quality of Care and Outcomes in Heart Failure: An Analysis of Get With The Guidelines® Heart Failure. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	16
124	Decline of Increased Risk Donor Offers on Waitlist Survival in Heart Transplantation. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2408-2409.	1.2	16
125	Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF). <i>American Journal of Cardiology</i> , 2018, 122, 1506-1512.	0.7	16
126	Stroke risk following implantation of current generation centrifugal flow left ventricular assist devices. <i>Journal of Cardiac Surgery</i> , 2020, 35, 383-389.	0.3	16

#	ARTICLE	IF	CITATIONS
127	Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF Registry. <i>Journal of Cardiac Failure</i> , 2022, 28, 370-384.	0.7	16
128	Donation after circulatory death heart transplantation in the United States: An early report of donor characteristics. <i>JTCVS Techniques</i> , 2022, 12, 104-107.	0.2	16
129	Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With Heart Failure and Diabetes. <i>JACC: Heart Failure</i> , 2022, 10, 198-210.	1.9	16
130	Trajectory of Congestion Metrics by Ejection Fraction in Patients With Acute Heart Failure (from the Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.7	15
131	Novel Biomarkers for the Risk Stratification of Heart Failure with Preserved Ejection Fraction. <i>Current Heart Failure Reports</i> , 2017, 14, 434-443.	1.3	15
132	Health Status Variation Across Practices in Outpatients With Heart Failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004668.	0.9	15
133	Characteristics of Acute Heart Failure Hospitalizations Based on Presenting Severity. <i>Circulation: Heart Failure</i> , 2019, 12, e005171.	1.6	15
134	Strict Versus Lenient Versus Poor Rate Control Among Patients With Atrial Fibrillation and Heart Failure (from the Get With The Guidelines "Heart Failure Program). <i>American Journal of Cardiology</i> , 2020, 125, 894-900.	0.7	15
135	Acute Hemodynamic Effects and Tolerability of Phosphodiesterase-1 Inhibition With ITI-214 in Human Systolic Heart Failure. <i>Circulation: Heart Failure</i> , 2021, 14, e008236.	1.6	15
136	Development and validation of a risk model for in-hospital worsening heart failure from the Acute Decompensated Heart Failure National Registry (ADHERE). <i>American Heart Journal</i> , 2016, 178, 198-205.	1.2	14
137	Cardiac safety research consortium "shock II" think tank report: Advancing practical approaches to generating evidence for the treatment of cardiogenic shock. <i>American Heart Journal</i> , 2020, 230, 93-97.	1.2	14
138	Association of Dual Eligibility for Medicare and Medicaid With Heart Failure Quality and Outcomes Among Get With The Guidelines "Heart Failure Hospitals. <i>JAMA Cardiology</i> , 2021, 6, 791.	3.0	14
139	Intra-Aortic Balloon Pump Use Before Left Ventricular Assist Device Implantation: Insights From the INTERMACS Registry. <i>ASAIO Journal</i> , 2018, 64, 218-224.	0.9	13
140	Timing of Postdischarge Follow-Up and Medication Adherence Among Patients With Heart Failure. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	13
141	A Hospital Level Analysis of 30-Day Readmission Performance for Heart Failure Patients and Long-Term Survival: Findings from Get With The Guidelines-Heart Failure. <i>American Heart Journal</i> , 2018, 200, 127-133.	1.2	13
142	Percutaneous coronary intervention outcomes in patients with stable coronary disease and left ventricular systolic dysfunction. <i>ESC Heart Failure</i> , 2019, 6, 1233-1242.	1.4	13
143	Early outcomes with durable left ventricular assist device replacement using the HeartMate 3. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 160, 132-139.e1.	0.4	13
144	Quality of Care and Outcomes Among Medicare Advantage vs Fee-for-Service Medicare Patients Hospitalized With Heart Failure. <i>JAMA Cardiology</i> , 2020, 5, 1349.	3.0	13

#	ARTICLE	IF	CITATIONS
145	Testing for Coronary Artery Disease in Older Patients With New-Onset Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e006963.	1.6	13
146	Association of Heart Failure With Outcomes Among Patients With Peripheral Artery Disease: Insights From EUCLID. <i>Journal of the American Heart Association</i> , 2021, 10, e018684.	1.6	13
147	Economic Evaluation of Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure With Reduced Ejection Fraction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e007094.	0.9	13
148	The Risk of Stroke on Left Ventricular Assist Device Support. <i>JACC: Heart Failure</i> , 2017, 5, 712-714.	1.9	12
149	Association of Visit-to-Visit Variability in Kidney Function and Serum Electrolyte Indexes With Risk of Adverse Clinical Outcomes Among Patients With Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 68-77.	3.0	12
150	Predischarge initiation of Ivabradine in the Management of Heart Failure: Results of the PRIME-HF Trial. <i>American Heart Journal</i> , 2020, 223, 98-105.	1.2	12
151	Proteomic profiling identifies CLEC4C expression as a novel biomarker of primary graft dysfunction after heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 1589-1598.	0.3	12
152	Impact of Current Versus Previous Cardiac Resynchronization Therapy Guidelines on the Proportion of Patients With Heart Failure Eligible for Therapy. <i>JACC: Heart Failure</i> , 2017, 5, 388-392.	1.9	11
153	Angiotensin-Neprilysin Inhibition in Black Americans. <i>JACC: Heart Failure</i> , 2020, 8, 859-866.	1.9	11
154	Reducing ECG Artifact From Left Ventricular Assist Device Electromagnetic Interference. <i>Journal of the American Heart Association</i> , 2020, 9, e017563.	1.6	11
155	Trends and outcomes of cardiac transplantation from donors dying of drug intoxication. <i>American Heart Journal</i> , 2018, 199, 92-96.	1.2	10
156	The emerging role of novel antihyperglycemic agents in the treatment of heart failure and diabetes: A focus on cardiorenal outcomes. <i>Clinical Cardiology</i> , 2018, 41, 1259-1267.	0.7	10
157	Contemporary Use of Venoarterial Extracorporeal Membrane Oxygenation: Insights from the Multicenter RESCUE Registry. <i>Journal of Cardiac Failure</i> , 2021, 27, 327-337.	0.7	10
158	EXPANDING the Donor Pool: Quantifying the Potential Impact of a Portable Organ-Care System for Expanded Criteria Heart Donation. <i>Journal of Cardiac Failure</i> , 2021, 27, 1462-1465.	0.7	10
159	Diuretic Changes, Health Care Resource Utilization, and Clinical Outcomes for Heart Failure With Reduced Ejection Fraction: From the Change the Management of Patients With Heart Failure Registry. <i>Circulation: Heart Failure</i> , 2021, 14, e008351.	1.6	10
160	Is the affordable care act medicaid expansion associated with receipt of heart failure guideline-directed medical therapy by race and ethnicity?. <i>American Heart Journal</i> , 2022, 244, 135-148.	1.2	10
161	Prescription of Guideline-Recommended Implantable Cardioverter Defibrillator and Cardiac Resynchronization Therapy Among Patients Hospitalized With Heart Failure and Varying Degrees of Renal Function. <i>American Journal of Cardiology</i> , 2017, 119, 886-892.	0.7	9
162	Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy. <i>JACC: CardioOncology</i> , 2019, 1, 273-279.	1.7	9

#	ARTICLE	IF	CITATIONS
163	The Maximally Tolerated Dose. <i>JACC: Heart Failure</i> , 2020, 8, 739-741.	1.9	9
164	Innovations in Heart Transplantation: A Review. <i>Journal of Cardiac Failure</i> , 2022, 28, 467-476.	0.7	9
165	The Future of heart procurement with donation after circulatory death: Current practice and opportunities for advancement. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 1385-1390.	0.3	9
166	Differences in health care use and outcomes by the timing of in-hospital worsening heart failure. <i>American Heart Journal</i> , 2015, 170, 1124-1132.	1.2	8
167	Heart failure medications prescribed at discharge for patients with left ventricular assist devices. <i>American Heart Journal</i> , 2016, 179, 99-106.	1.2	8
168	Cangrelor use prior to left ventricular assist device surgery: a case series. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 131-133.	1.0	8
169	PROVIDE-HF primary results: Patient-Reported Outcomes in Investigation following Initiation of Drug therapy with Entresto (sacubitril/valsartan) in heart failure. <i>American Heart Journal</i> , 2020, 230, 35-43.	1.2	8
170	Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2020, 13, e006758.	1.6	8
171	Temporal trends in risk profiles among patients hospitalized for heart failure. <i>American Heart Journal</i> , 2021, 232, 154-163.	1.2	8
172	Growth differentiation factor-15, treatment with liraglutide, and clinical outcomes among patients with heart failure. <i>ESC Heart Failure</i> , 2021, 8, 2608-2616.	1.4	8
173	The association of improvement in left ventricular ejection fraction with outcomes in patients with heart failure with reduced ejection fraction: data from CHAMP-HF. <i>European Journal of Heart Failure</i> , 2022, 24, 762-770.	2.9	8
174	Outcomes and cost among Medicare beneficiaries hospitalized for heart failure assigned to accountable care organizations. <i>American Heart Journal</i> , 2020, 226, 13-23.	1.2	7
175	Trends in Treatment for Patients Hospitalized with Heart Failure with Preserved Ejection Fraction Before and After Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT). <i>American Journal of Cardiology</i> , 2020, 125, 1655-1660.	0.7	7
176	Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities. <i>American Heart Journal</i> , 2021, 235, 82-96.	1.2	7
177	Association between sacubitril/valsartan initiation and real-world health status trajectories over 18 months in heart failure with reduced ejection fraction. <i>ESC Heart Failure</i> , 2021, 8, 2670-2678.	1.4	7
178	Health System Level Performance in Prescribing Guideline-Directed Medical Therapy for Patients with HFrEF: Results from the CONNECT-HF Trial. <i>Journal of Cardiac Failure</i> , 2022, , .	0.7	7
179	Heart Failure Clinical Trial Operations During the COVID-19 Pandemic. <i>Circulation: Heart Failure</i> , 2020, 13, e007456.	1.6	6
180	Treatment Persistence of Renin-Angiotensin-Aldosterone-System Inhibitors Over Time in Heart Failure with Reduced Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2022, 28, 191-201.	0.7	6

#	ARTICLE	IF	CITATIONS
181	Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction After a Recent Worsening Heart Failure Event. <i>Journal of the American Heart Association</i> , 2021, 10, e021276.	1.6	6
182	PARAGON-HF Clinical Trial Eligibility in a Population of Patients Hospitalized With Heart Failure. <i>Journal of Cardiac Failure</i> , 2019, 25, 1009-1011.	0.7	5
183	Glycated Hemoglobin and Outcomes of Heart Failure (from Get With the Guidelines-Heart Failure). <i>American Journal of Cardiology</i> , 2019, 123, 618-626.	0.7	5
184	Renal Outcomes in Patients Bridged to Heart Transplant With a Left Ventricular Assist Device. <i>Annals of Thoracic Surgery</i> , 2020, 110, 567-574.	0.7	5
185	Evidence-Based Process Performance Measures and Clinical Outcomes in Patients With Incident Heart Failure With Reduced Ejection Fraction: A Danish Nationwide Cohort Study. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2022, 15, CIRCOUTCOMES121007973.	0.9	5
186	Chest pain in patients with heart failure: why history may matter. <i>European Heart Journal</i> , 2014, 35, 3408-3409.	1.0	4
187	Comparison of Clinical Characteristics and Outcomes of Patients With Versus Without Diabetes Mellitus and With Versus Without Angina Pectoris (from the Duke Databank for Cardiovascular) Tj ETQq1 1 0.784314 rgBT /@verlock	1.4	4
188	Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 298-307.	1.9	4
189	Mineralocorticoid Receptor Antagonism for the Treatment of AF and HFpEF. <i>JACC: Heart Failure</i> , 2018, 6, 698-700.	1.9	4
190	Health-Related Quality of Life in Comorbid Heart Failure With Reduced Ejection Fraction and Diabetes Mellitus. <i>Journal of the American College of Cardiology</i> , 2019, 74, 3176-3178.	1.2	4
191	Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors Among Medicare Beneficiaries Hospitalized for Heart Failure. <i>Journal of Cardiac Failure</i> , 2022, 28, 554-563.	0.7	4
192	A Machine Without an Owner's Manual. <i>JACC: Heart Failure</i> , 2016, 4, 218-219.	1.9	3
193	ASSOCIATION BETWEEN SERUM POTASSIUM LEVEL AND OUTCOMES IN HEART FAILURE WITH REDUCED EJECTION FRACTION: A COHORT STUDY FROM THE SWEDISH HEART FAILURE REGISTRY. <i>Journal of the American College of Cardiology</i> , 2017, 69, 678.	1.2	3
194	Blood Pressure Response during Cardiopulmonary Exercise Testing in Heart Failure. <i>Medicine and Science in Sports and Exercise</i> , 2018, 50, 1345-1349.	0.2	3
195	Influenza Vaccination in Patients With Heart Failure. <i>Circulation</i> , 2019, 139, 587-589.	1.6	3
196	EFFECT OF SACUBITRIL/VALSARTAN INITIATION ON 30-DAY READMISSIONS AFTER A HOSPITALIZATION FOR ACUTE DECOMPENSATED HEART FAILURE: A SECONDARY ANALYSIS OF THE PIONEER-HF TRIAL. <i>Journal of the American College of Cardiology</i> , 2019, 73, 901.	1.2	3
197	Biomarkers in Advanced Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e006840.	1.6	3
198	Percutaneous coronary intervention in patients with stable coronary artery disease and left ventricular systolic dysfunction: insights from the VA CART program. <i>American Heart Journal</i> , 2021, 235, 149-157.	1.2	3

#	ARTICLE	IF	CITATIONS
199	Profile of Patients Hospitalized for Heart Failure Who Leave Against Medical Advice. <i>Journal of Cardiac Failure</i> , 2021, 27, 747-755.	0.7	3
200	Getting to a Man's Heart through His Colon. <i>Texas Heart Institute Journal</i> , 2016, 43, 168-170.	0.1	3
201	Relationship between Hospital 30-Day Mortality Rates for Heart Failure and Patterns of Early Inpatient Comfort Care. <i>Journal of Hospital Medicine</i> , 2018, 13, 170-176.	0.7	3
202	VAD therapy 20/20: moving beyond the myopic view of a nascent therapy. <i>Annals of Cardiothoracic Surgery</i> , 2014, 3, 603-5.	0.6	3
203	Identifying patients at increased risk for poor outcomes from heart failure with reduced ejection fraction: the PROMPT-HF risk model. <i>ESC Heart Failure</i> , 2022, 9, 178-185.	1.4	3
204	Clinical trajectory of patients with a worsening heart failure event and reduced ventricular ejection fraction. <i>American Heart Journal</i> , 2022, 245, 110-116.	1.2	3
205	Angiotensin Receptor Neprilysin Inhibition and Associated Outcomes by Race and Ethnicity in Patients With Heart Failure With Reduced Ejection Fraction: Data From CHAMP-HF. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	3
206	Evolving the Hospital Readmissions Reduction Program. <i>Journal of the American College of Cardiology</i> , 2019, 74, 235-237.	1.2	2
207	Haemoconcentration during treatment of acute heart failure with cardiorenal syndrome: from the CARRESS-HF trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1472-1476.	2.9	2
208	ICDs Are Still an Effective Therapy to Prevent Sudden Cardiac Death in Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 907-910.	1.9	2
209	Comparative Effectiveness of Primary Prevention Implantable Cardioverter-Defibrillators in Older Heart Failure Patients With Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2020, 9, e012405.	1.6	2
210	Incorporating Patient Preferences Into Hospital Quality Metrics for Heart Failure. <i>JAMA Cardiology</i> , 2021, 6, 177.	3.0	2
211	Risk Adjustment Model for Preserved Health Status in Patients With Heart Failure and Reduced Ejection Fraction: The CHAMP-HF Registry. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e008072.	0.9	2
212	Low Blood Pressure Threshold for Adverse Outcomes During Left Ventricular Assist Device Support. <i>American Journal of Cardiology</i> , 2022, 169, 78-85.	0.7	2
213	Improving implementation of evidence-based therapies for heart failure. <i>Clinical Cardiology</i> , 2022, 45, .	0.7	2
214	Embolism after Inferior Vena Cava Filter Mesh Fragmentation. <i>Journal of Vascular and Interventional Radiology</i> , 2010, 21, 1782-1784.	0.2	1
215	Digoxin initiation is associated with lower risk of all-cause readmission after hospitalisation for heart failure. <i>Evidence-Based Medicine</i> , 2014, 19, 153-153.	0.6	1
216	Assessment of cardiac allograft systolic function by global longitudinal strain: From donor to recipient. <i>Clinical Transplantation</i> , 2017, 31, e12961.	0.8	1

#	ARTICLE	IF	CITATIONS
217	Rethinking papillary muscle resection for refractory ventricular tachycardia in the LVAD era. A case report. <i>Journal of Electrocardiology</i> , 2017, 50, 964-965.	0.4	1
218	TCT-591 First-in-Human Experience with Aortix Intra-Aortic Pump. <i>Journal of the American College of Cardiology</i> , 2017, 70, B244-B245.	1.2	1
219	In-hospital initiation of sacubitril/valsartan in acute decompensated heart failure: being in the right place at the right time. <i>European Journal of Heart Failure</i> , 2019, 21, 1008-1011.	2.9	1
220	EFFECT OF SACUBITRIL/VALSARTAN ON BIOMARKERS OF MYOCARDIAL STRESS IN PATIENTS HOSPITALIZED WITH ACUTE HEART FAILURE IN PIONEER-HF. <i>Journal of the American College of Cardiology</i> , 2019, 73, 682.	1.2	1
221	From Theory to Practice. <i>JACC: Heart Failure</i> , 2020, 8, 55-56.	1.9	1
222	Lawn Mower Versus Left Ventricular Assist Device. <i>JACC: Case Reports</i> , 2020, 2, 406-410.	0.3	1
223	Response to Letter Regarding Article, "Selecting a Noninvasive Imaging Study After an Inconclusive Exercise Test". <i>Circulation</i> , 2011, 123, .	1.6	0
224	Clinical Characteristics and Outcomes of Patients with Discordant Findings at Right Heart Catheterization and Cardiopulmonary Exercise Testing. <i>Journal of Cardiac Failure</i> , 2014, 20, S49-S50.	0.7	0
225	Ascending Aorta to Main Pulmonary Artery Fistula Following Orthotopic Heart Transplantation. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, e25-e27.	1.1	0
226	Trends in the Use of Guideline-based Therapies Among Dialysis Patients Hospitalized with Heart Failure: Findings from Get With The Guidelines-Heart Failure. <i>Journal of Cardiac Failure</i> , 2015, 21, S114-S115.	0.7	0
227	Measuring heart failure quality: does perfection matter?. <i>Heart</i> , 2015, 101, 1691-1692.	1.2	0
228	What's Harder: Seeing a Doctor or Reducing Readmissions?—. <i>JACC: Heart Failure</i> , 2015, 3, 774-776.	1.9	0
229	Regional Differences during Acute Heart Failure Hospitalizations of Patients with Heart Failure with Preserved Ejection Fraction: Insights From ASCEND-HF. <i>Journal of Cardiac Failure</i> , 2016, 22, S27.	0.7	0
230	Response to Letter Regarding Article, "Temporal Trends and Variation in Early Scheduled Follow-up After a Hospitalization for Heart Failure: Findings from Get With The Guidelines-Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	0
231	HEMOCONCENTRATION DURING MANAGEMENT OF PATIENTS WITH ACUTE HEART FAILURE AND CARDIORENAL SYNDROME: INSIGHTS FROM CARRESS-HF. <i>Journal of the American College of Cardiology</i> , 2017, 69, 767.	1.2	0
232	THE IMPACT OF THE CURRENT VERSUS PRIOR CARDIAC RESYNCHRONIZATION GUIDELINES ON THE PROPORTION OF HOSPITALIZED HEART FAILURE PATIENTS ELIGIBLE FOR THERAPY. <i>Journal of the American College of Cardiology</i> , 2017, 69, 784.	1.2	0
233	A HOSPITAL LEVEL ANALYSIS OF 30-DAY READMISSION RATES FOR HEART FAILURE PATIENTS AND LONG-TERM SURVIVAL AMONG HIGHEST AND LOWEST PERFORMING HOSPITALS, FINDINGS FROM GET WITH THE GUIDELINES-HEART FAILURE. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2565.	1.2	0
234	Improving heart failure health: is there a secret Swedish sauce?. <i>European Journal of Heart Failure</i> , 2017, 19, 1117-1118.	2.9	0

#	ARTICLE	IF	CITATIONS
235	Can walking patients with heart failure and preserved ejection fraction tell us who should walk also to the catheterization laboratory or just walk home?. European Journal of Heart Failure, 2018, 20, 723-724.	2.9	0
236	Preventing Heart Failure in Diabetes. JACC: Heart Failure, 2018, 6, 831-832.	1.9	0
237	PROVIDER PERSPECTIVES ON THE FEASIBILITY AND UTILITY OF ROUTINE PATIENT-REPORTED OUTCOMES ASSESSMENT IN HEART FAILURE: A QUALITATIVE ANALYSIS. Journal of the American College of Cardiology, 2019, 73, 971.	1.2	0
238	Heart Failure Management Under Pressure. Journal of the American College of Cardiology, 2019, 73, 3064-3066.	1.2	0
239	Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized with Heart Failure. Journal of Cardiac Failure, 2019, 25, S151.	0.7	0
240	RAAS Inhibition to Prevent GI Bleeding. Journal of the American College of Cardiology, 2019, 73, 1779-1780.	1.2	0
241	Should Hepatitis C Donors Be Used in Naïve Urgent Status Patients on the Heart Transplant Waitlist?. Current Transplantation Reports, 2019, 6, 106-108.	0.9	0
242	A Case of Rare Inherited Restrictive Cardiomyopathy With Severe Batrial Enlargement. JACC: Case Reports, 2019, 1, 588-591.	0.3	0
243	Reply. JACC: Heart Failure, 2019, 7, 85.	1.9	0
244	Quality and Outcomes in Heart Failure. , 2020, , 697-704.e2.		0
245	Benefits of Optimizing Heart Failure Medication Dosage. Journal for Nurse Practitioners, 2020, 16, 498-503.	0.4	0
246	Can we prevent infections in patients with left ventricular assist devices?. European Journal of Heart Failure, 2021, 23, 1416-1418.	2.9	0
247	A Case for Re-Gifting. JACC: Case Reports, 2021, 3, 1010-1012.	0.3	0
248	HCV Positive Allograft Use in Heart Transplant: A Silver Lining to an Epidemic. Journal of Cardiac Failure, 2021, , .	0.7	0
249	Trends in Cardiovascular Medicine: Update on Cardiac Transplantation. Trends in Cardiovascular Medicine, 2021, , .	2.3	0
250	A Hospital and Postdischarge Quality Improvement Intervention and Outcomes and Care for Patients With Heart Failure With Reduced Ejection Fractionâ€”Reply. JAMA - Journal of the American Medical Association, 2021, 326, 1977.	3.8	0
251	Association of tacrolimus timeâ€”toâ€”therapeutic range on renal dysfunction and acute cellular rejection after orthotopic heart transplantation in a high use basiliximab population. Clinical Transplantation, 2021, , e14542.	0.8	0
252	Association of readmission penalty amount with subsequent 30-day risk standardized readmission and mortality rates among patients hospitalized with heart failure: An analysis of get with the guidelines â€” heart failure participating centers. American Heart Journal, 2022, 246, 1-11.	1.2	0

#	ARTICLE	IF	CITATIONS
253	Poor Medication Adherence Is Associated With Worse Health Status In Heart Failure With Reduced Ejection Fraction. Journal of Cardiac Failure, 2022, 28, S119.	0.7	0